GR852877B - - Google Patents

Info

Publication number
GR852877B
GR852877B GR852877A GR850102877A GR852877B GR 852877 B GR852877 B GR 852877B GR 852877 A GR852877 A GR 852877A GR 850102877 A GR850102877 A GR 850102877A GR 852877 B GR852877 B GR 852877B
Authority
GR
Greece
Application number
GR852877A
Other languages
Greek (el)
Inventor
Andrew John Garman
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10570497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR852877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of GR852877B publication Critical patent/GR852877B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
GR852877A 1984-11-30 1985-11-29 GR852877B (en0)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848430252A GB8430252D0 (en) 1984-11-30 1984-11-30 Compounds

Publications (1)

Publication Number Publication Date
GR852877B true GR852877B (en0) 1986-03-31

Family

ID=10570497

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852877A GR852877B (en0) 1984-11-30 1985-11-29

Country Status (9)

Country Link
US (1) US4935465A (en0)
EP (1) EP0183503B1 (en0)
JP (2) JPH0717517B2 (en0)
AU (1) AU5044585A (en0)
DE (1) DE3586313T2 (en0)
DK (1) DK552285A (en0)
GB (1) GB8430252D0 (en0)
GR (1) GR852877B (en0)
PT (1) PT81581B (en0)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842868A (en) * 1986-09-26 1989-06-27 Helwing Robert F Covalently bonded active agents with carbonium ion base groups
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
JPH079429B2 (ja) * 1988-10-12 1995-02-01 財団法人化学及血清療法研究所 人工担体およびその製造方法
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
FI901810A7 (fi) * 1989-04-13 1990-10-14 Vascular Laboratory Inc Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5767072A (en) * 1989-09-14 1998-06-16 Board Of Regents, The University Of Texas System Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0676965T3 (da) 1992-11-16 2007-11-19 Centocor Inc Fremgangsmåde til at reducere immunogeniciteten af variable regioner på antistoffer
EP0675727B1 (en) * 1992-12-10 2002-04-10 Enzon, Inc. Glycolipid enzyme-polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
EP0773975A4 (en) * 1994-08-04 1998-06-10 Gordon George Wallace CONDUCTIVE ELECTROACTIVE BIOMATERIALS
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
EP0796324A1 (en) * 1994-12-07 1997-09-24 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6428790B1 (en) * 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
DK0876165T3 (da) 1995-12-18 2007-08-06 Angiotech Biomaterials Corp Tværbundne polymersammensætninger og fremgangsmåder til deres fremstilling
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
JPH11502255A (ja) * 1995-12-29 1999-02-23 ザ、プロクター、エンド、ギャンブル、カンパニー 固定化酵素を含有する洗剤組成物
CA2242488A1 (en) * 1996-02-15 1997-08-21 Novo Nordisk A/S Conjugation of polypeptides
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001503396A (ja) * 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
JPH10276776A (ja) * 1997-04-07 1998-10-20 Toyobo Co Ltd 可逆的に不活化された耐熱性ｄｎａポリメラーゼ
EP1075511A1 (en) 1998-05-08 2001-02-14 University Of Southern California Size enhanced fibrinolytic enzymes
IL139786A0 (en) * 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN1244376C (zh) * 1999-04-23 2006-03-08 阿尔萨公司 可释放的键和含有该键的组合物
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
WO2001004287A1 (en) * 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
US6423666B1 (en) 1999-10-05 2002-07-23 Bio-Rad Laboratories, Inc. Large-pore chromatographic beads prepared by suspension polymerization
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
GB0123232D0 (en) * 2001-09-26 2001-11-21 Smith & Nephew Polymers
US20040186051A1 (en) * 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
AU2003247609A1 (en) 2002-06-24 2004-01-06 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
DE60331367D1 (de) * 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040151766A1 (en) * 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
GB0305989D0 (en) * 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
EP1673387B1 (en) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1748795A1 (en) * 2004-04-21 2007-02-07 Alza Corporation Polymer conjugate releasable under mild thiolytic conditions
BRPI0510477B1 (pt) 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation Método para formar um gel e dispositivo para uso em aplicações médicas
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
JP2010508271A (ja) 2006-10-27 2010-03-18 ウェイ‐チャン シェン 脂質化インターフェロンおよびその使用
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
WO2009036349A1 (en) * 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
MX2010004400A (es) 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
JP2011502520A (ja) * 2007-11-09 2011-01-27 アナフォア インコーポレイテッド 疾患治療のためのマンノース結合レクチンの融合タンパク質
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
US20110318322A1 (en) * 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
GB201117428D0 (en) * 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
KR102172897B1 (ko) 2012-06-08 2020-11-02 서트로 바이오파마, 인크. 부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
DK3584255T3 (da) 2012-08-31 2022-04-04 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
PE20170950A1 (es) 2014-10-24 2017-07-13 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TWI853819B (zh) 2018-06-21 2024-09-01 瑞士商西萊絲蒂亞生物科技股份有限公司 胺基二芳基醚的製備方法
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN119455004A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
EA202192394A1 (ru) 2019-04-10 2022-01-24 Селлестия Биотек Аг Ингибиторы пути передачи сигнала notch и их применение для лечения рака
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
EP4255409A1 (en) 2020-12-07 2023-10-11 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
CN112451681B (zh) * 2020-12-09 2023-08-25 苏州大学 酸敏感型聚合物-药物偶联物及其制备和应用
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1059670A (en) * 1964-12-05 1967-02-22 Cassella Farbwerke Mainkur Ag Process for the addition of maleic anhydride to polyalkylene ethers
GB1390716A (en) * 1972-06-27 1975-04-16 Mitsubishi Electric Corp Ester of trimellitic anhydride and process for producing the same
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0038154B1 (en) * 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS58225025A (ja) * 1982-06-24 1983-12-27 Nippon Chem Res Kk 効力持続性組成物
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4859736A (en) * 1987-03-30 1989-08-22 Ciba-Geigy Corporation Synthetic polystyrene resin and its use in solid phase peptide synthesis

Also Published As

Publication number Publication date
DE3586313D1 (de) 1992-08-13
JP2545339B2 (ja) 1996-10-16
JPS61155333A (ja) 1986-07-15
EP0183503B1 (en) 1992-07-08
US4935465A (en) 1990-06-19
JPH0717517B2 (ja) 1995-03-01
GB8430252D0 (en) 1985-01-09
DK552285A (da) 1986-05-31
PT81581B (en) 1987-07-22
EP0183503A2 (en) 1986-06-04
DE3586313T2 (de) 1993-01-21
PT81581A (en) 1985-12-01
JPH06279318A (ja) 1994-10-04
EP0183503A3 (en) 1988-01-07
DK552285D0 (da) 1985-11-28
AU5044585A (en) 1986-07-17

Similar Documents

Publication Publication Date Title
AT379850B (en0)
AU2219783A (en0)
AU2557584A (en0)
BE900712A (en0)
BG38294A1 (en0)
BG39778A1 (en0)
BG44718A1 (en0)
BG44723A1 (en0)
BG44737A1 (en0)
BG44749A1 (en0)
BG44806A1 (en0)
BG44829A1 (en0)
BG44830A1 (en0)
BG44848A1 (en0)
BG44917A1 (en0)
BG44933A1 (en0)
BG44935A1 (en0)
BG45025A1 (en0)
BG45054A1 (en0)
BG45060A1 (en0)
BG45079A1 (en0)
BG45080A1 (en0)
BG45091A1 (en0)
BG45092A1 (en0)
BG45094A1 (en0)